SUO 2019 the value of critical assessment of one’s own institution’s outcomes to drive patient outcomes, innovations that have led to current phase I and phase II trials, UTSW SAbR experience.
erectile dysfunction, inflatable penile prosthesis (IPP), Satisfaction Survey for Inflatable Penile Implant (SSIPI), better patient care for Spanish speaking individuals undergoing inflatable penile prosthesis surgery.
At the 2025 UCSF-UCLA PSMA Conference, Amir Iravani compares FDA-approved PSMA PET agents (gallium-68 PSMA-11, DCFPyL, rhPSMA-7.3) for prostate cancer imaging. Dr. Iravani notes similar…
Peyronie’s Disease, Molecular Hallmarks of Peyronie’s Disease, tyrosine kinase inhibitor, transforming growth factor-beta (TGF-β), Matrix metalloproteinases (MMP) enzymes, Tissue inhibitors of metalloproteinases proteins (TIMP), pirfenidone,…
Testicular cancer, Testicular germ cell tumor (TGCT), Retroperitoneal Lymph Node Dissection (RPLND), pathological lymph node staging, clinical stage (CS) II seminomatous TGCT.
Benign prostatic hyperplasia (BPH), lower urinary tract symptoms (LUTS), Holmium Laser Enucleation of the prostate cancer (HoLEP), Advancing Holmium Laser Enucleation, American Urological Association Symptom…
Oliver Sartor host Ken Herrmann to discuss tumor dosimetry findings from a VISION trial substudy examining lutetium PSMA therapy in prostate cancer patients. Dr. Herrmann…
Fecal Incontinence, Sacral neuromodulation, sacral nerve stimulation (SNS), Sacral Nerve Stimulator for Management of Fecal Incontinence, overactive bladder, InterStim™ device.
UroToday – GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and…
Ashish Kamat speaks with Nimira Alimohamed about the evolution of circulating tumor DNA (ctDNA) in muscle invasive bladder cancer management. Dr. Alimohamed explains that current…
Treatment options for metastatic urothelial carcinoma, cisplatin-based chemotherapy, combination enfortumab vedotin–pembrolizumab, Nivolumab as adjuvant treatment in high-risk muscle-invasive UC.
